Eptinezumab (Vyepti®). HTA ID: 22052

Assessment Status Rapid review complete
HTA ID 22052
Drug Eptinezumab
Brand Vyepti®
Indication For the prophylaxis of migraine in adults who have at least four migraine days per month
Assessment Process
Rapid review commissioned 20/07/2022
Rapid review completed 16/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of eptinezumab (Vyepti®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies*

This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. June 2023